<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505944</url>
  </required_header>
  <id_info>
    <org_study_id>NLG-MCL7</org_study_id>
    <secondary_id>2017-001060-38</secondary_id>
    <nct_id>NCT03505944</nct_id>
  </id_info>
  <brief_title>Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma</brief_title>
  <acronym>VALERIA</acronym>
  <official_title>Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Lymphoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Lymphoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of
      rituximab-lenalidomide in patients with relapsed/refractory MCL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>6 months</time_frame>
    <description>The primary objective is to assess the overall response rate (ORR) at 6 months with lenalidomide-venetoclax and rituximab, in patients with relapsed or refractory mantle cell lymphoma, by use of an MRD driven strategy. ORR includes complete (CR) and partial remissions (PR).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Relapsed Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax+lenalidomide+rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>venetoclax + lenalidomide + rituximab</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Age &gt;18 years

          -  Histologically confirmed (according to the WHO 2016 classification) mantle cell
             lymphoma stage I-IV

               -  Who have received at least 1 prior rituximab-containing chemotherapy regimen,
                  with documented relapse or disease progression following the last anti-MCL
                  treatment OR

               -  Are not considered to be candidates for chemotherapy due to frailty or
                  comorbidity

          -  At least 1 measurable site of disease (&gt;1.5 cm long axis)

          -  WHO performance status 0 - 3

          -  Written informed consent.

          -  Female subjects of childbearing potential must (see page 52 for definition of not
             fertile):

               -  Understand that the study medication is expected to be teratogenic

               -  Agree to use, and be able to comply with, highly effective contraception without
                  interruption, 4 weeks before starting study drug, throughout study drug therapy
                  (including dose interruptions) and for 4 weeks after the end of study drug
                  therapy, even if she has amenorrhoea.

               -  All fertile women must agree to perform monthly pregnancy tests while on study
                  medication and until 4 weeks after completion of study drug. Tests must have a
                  minimum sensitivity of 25 mIE/ml and be medically witnessed

               -  Highly effective contraception include:

        Implant* Levonorgestrel-releasing intrauterine system (IUS)* Medroxyprogesterone acetate
        depot Tubal sterilisation Sexual intercourse with a vasectomised male partner only;
        vasectomy must be confirmed by two negative semen analyses Ovulation inhibitory
        progesterone-only pills (i.e., desogestrel) NB! Patients using a hormonal method, must also
        use a second barrier method. Sexual abstinence (if refraining from heterosexual intercourse
        during the entire period of risk associated with the study treatments. The reliability of
        sexual abstinence needs to be evaluated in relation to the preferred and usual lifestyle of
        the subject).

          -  Male subjects must

               -  Agree to use condoms throughout study drug therapy, during any dose interruption
                  and for one week after cessation of study therapy if their partner is of
                  childbearing potential and has no contraception.

               -  Agree not to donate semen during study drug therapy and for one week after end of
                  study drug therapy.

          -  All subjects must

               -  Agree to abstain from donating blood while taking study drug therapy and for one
                  week following discontinuation of study drug therapy.

               -  Agree not to share study medication with another person and to return all unused
                  study drug to the investigator

        Exclusion criteria

          -  Chemotherapy or radiotherapy within 3 weeks

          -  Therapeutic antibodies or BTK inhibitors within 4 weeks

          -  Radioimmunotherapy within 10 weeks

          -  Major surgery within 4 weeks of inclusion in this trial.

          -  Previous treatment with venetoclax

          -  Impaired liver function: AST and ALT &gt;3.0 × the upper normal limit (ULN) of
             institution's normal range; Bilirubin &gt; 1.5 × ULN. Subjects with Gilbert's Syndrome
             may have a bilirubin &gt; 1.5 × ULN, per discussion between the investigator and medical
             monitor. Elevated Bilirubin due to haemolytic anemia or caused by lymphoma, is not an
             exclusion criterion.

          -  Absolute neutrophil count (ANC) &lt;1.0x 109, unless caused by bone marrow infiltration
             by lymphoma.

          -  Platelet count &lt;60 x 109, unless caused by bone marrow infiltration by lymphoma.

          -  Creatinine clearance below 50 ml/min (Cockcroft-Gault)

          -  Known CNS lymphoma.

          -  Heart failure in NYHA stage IV or other serious CVD

          -  Pulmonary failure (ex chronic disease with hypoxemia)

          -  Active serious infections such as hepatitis B or C and HIV

          -  Conditions with serious immunocompromised state

          -  Breastfeeding women must be excluded or stop breastfeeding

          -  Other active malignancy.

          -  Psychiatric illness or condition which could interfere with the subjects' ability to
             understand the requirements of the study.

          -  Requirement of corticosteroid therapy at a dose &gt;10 mg prednisolone/day.

          -  Hypersensitivity to venetoclax, lenalidomide or rituximab, or HACA against rituximab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Jerkeman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mats Jerkeman, MD</last_name>
    <phone>+46 46177520</phone>
    <email>mats.jerkeman@med.lu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kasper Røikjær Jensen</last_name>
      <email>krj@rn.dk</email>
    </contact>
    <investigator>
      <last_name>Kasper Røikjær Jensen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Bentzen</last_name>
      <email>hansbent@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Hans Bentzen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic of Hematology L-4241 Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Hutchings</last_name>
      <email>Martin.hutchings@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Martin Hutchings</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology X Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacob Haaber Christensen</last_name>
      <email>Jacob.h.christensen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Jacob Haaber Christensen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hæmatologisk Afdeling Zeeland University Hospital, Roskilde</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Bjørn Poulsen</last_name>
      <email>cbpo@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Christian Bjørn Poulsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology Helsinki University Hospital Comprehensive Cancer Center</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annika Pasanen</last_name>
      <email>Annika.pasanen@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Annika Pasanen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanne Kuitunen</last_name>
      <email>hanne.kuitunen@ppshp.fi</email>
    </contact>
    <investigator>
      <last_name>Hanne Kuitunen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marjukka Pollari</last_name>
      <email>Marjukka.pollari@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Marjukka Pollari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arne Kolstad</last_name>
      <email>arnek@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Arne Kolstad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Idun Bakke Bo</last_name>
      <email>idun.bakke.bo@sus.no</email>
    </contact>
    <investigator>
      <last_name>Idun Bakke Bo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Olav Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Wader</last_name>
      <email>karin.wader@stolav.no</email>
    </contact>
    <investigator>
      <last_name>Karin Wader</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingemar Lagerlöf</last_name>
      <email>ingemar.lagerlof@regionostergotland.se</email>
    </contact>
    <investigator>
      <last_name>Ingemar Lagerlöf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine Sunderbyn Hospital</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lena Brandefors</last_name>
      <email>Lena.Brandefors@nll.se</email>
    </contact>
    <investigator>
      <last_name>Lena Brandefors</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mats Jerkeman, MD</last_name>
      <phone>+46 4617 7520</phone>
      <email>mats.jerkeman@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Mats Jerkeman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Sonnevi</last_name>
      <email>kristina.sonnevi@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Kristina Sonnevi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology Norrland University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karin Papworth</last_name>
      <email>Karin.papworth@vll.se</email>
    </contact>
    <investigator>
      <last_name>Karin Papworth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsla Academic Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Glimelius</last_name>
      <email>ingrid.glimelius@igp.uu.se</email>
    </contact>
    <investigator>
      <last_name>Ingrid Glimelius</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

